erlotinib hydrochloride has been researched along with sirolimus in 75 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (sirolimus) | Trials (sirolimus) | Recent Studies (post-2010) (sirolimus) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 20,711 | 2,368 | 11,516 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | sirolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.25 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Mus musculus (house mouse) | 0.001 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0897 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.0042 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.225 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.225 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.9 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (26.67) | 29.6817 |
| 2010's | 51 (68.00) | 24.3611 |
| 2020's | 4 (5.33) | 2.80 |
| Authors | Studies |
|---|---|
| Adjei, A; Belani, CP | 1 |
| Kurisu, K; Okamura, T | 1 |
| Mancuso, A; Sternberg, CN | 1 |
| Cavenee, WK; Cloughesy, TF; Dia, EQ; Lu, KV; Mellinghoff, IK; Mischel, PS; Sawyers, CL; Shackleford, GM; Vivanco, I; Wang, MY; Zhu, S | 1 |
| Birle, DC; Hedley, DW | 1 |
| Brown, E; Buck, E; Eyzaguirre, A; Gibson, NW; Griffin, G; Haley, JD; Iwata, KK; McCormack, S; Petti, F | 1 |
| Altiok, S; Hidalgo, M; Iacobuzio-Donahue, C; Jimeno, A; Maitra, A; Mezzadra, H; Nielsen, ME; Rubio-Viqueira, B; Zhang, X | 1 |
| Chan, A; Chen, R; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P; Wheelhouse, J; Zhang, X | 1 |
| Costa, LJ; Drabkin, HA; Gemmill, RM | 1 |
| Jackman, D; Jänne, PA; Johnson, BE | 1 |
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Collins, MH; Cripe, TP; Johansson, G; Kim, MO; Kozma, SC; Lane, HA; Mahller, YY; Nobukuni, T; Perentesis, J; Ratner, N; Thomas, G | 1 |
| Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H | 1 |
| Fu, H; Hawk, N; Kauh, J; Khuri, FR; Ramalingam, SS; Sun, SY; Wang, X; Yue, P | 1 |
| Davidson, CR; Hardie, WD; Ikegami, M; Korfhagen, TR; Le Cras, TD; Schmidt, SM; Whitsett, JA | 1 |
| Choueiri, TK; Chowdhury, S | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Berger, W; Brandstetter, A; Filipits, M; Gruenberger, T; Herberger, B; Novak, S; Pirker, C; Puhalla, H; Schmid, K | 1 |
| España, A; López-Picazo, JM; López-Zabalza, MJ; Marquina, M; Pelacho, B; Pretel, M | 1 |
| Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Marcello, J; McLendon, RE; Norfleet, JA; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
| Mehta, SP | 1 |
| Abbruzzese, JL; Davis, D; Fogelman, D; Javle, MM; Reddy, SA; Shroff, RT; Varadhachary, GA; Wolff, RA; Xiong, H; Zhang, Y | 1 |
| Ikemura, S; Ishizaka, A; Kawada, I; Nakachi, I; Nakayama, S; Naoki, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Watanabe, H; Yasuda, H; Yoda, S | 1 |
| Bago-Horvath, Z; Berger, W; Cejka, D; Filipits, M; Haitel, A; Hayden, H; Herberger, B; Schmid, K; Sieghart, W; Werzowa, J | 1 |
| Chan, N; Lim, SW; Soo, RA; Teo, C; Wong, AS; Wong, E | 1 |
| Chiu, CW; Hanahan, D; Nozawa, H | 1 |
| Siu, LL | 1 |
| Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK | 1 |
| Hagymási, K; Tulassay, Z | 1 |
| Bendell, JC; Blobe, GC; Broadwater, G; Bullock, KE; Gockerman, JP; Howard, LA; Hurwitz, HI; Lager, JJ; Meadows, KL; Morse, MA; O'Neill, MM; Petros, WP; Truax, R; Uronis, HE; Younis, I; Zafar, SY | 1 |
| Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
| Amihai, D; Gilad, Y; Gorzalczany, Y; Hammel, I; Merimsky, O; Sagi-Eisenberg, R | 1 |
| Belousov, R; Colombo, C; Ghadimi, MP; Hornick, JL; Lazar, AJ; Lev, D; Liu, J; Lopez, G; Peng, T; Reynoso, D; Xie, X; Young, ED; Zhu, QS | 1 |
| Adès, L; Boehrer, S; Bouteloup, C; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Harper, F; Kroemer, G; Lainey, E; Pierron, G; Sébert, M; Tailler, M; Thépot, S | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V | 1 |
| Bago-Horvath, Z; Berger, W; Filipits, M; Grusch, M; Haitel, A; Hayden, H; Komina, O; Lackner, A; Pirker, C; Schmid, K; Sieghart, W; Węsierska-Gądek, J | 1 |
| Constantini, S; Kane, R; MacDonald, TJ; McCowage, G; Packer, RJ; Rood, B; Yalon, M | 1 |
| Bellail, AC; Gao, S; Hao, C; Li, B; Liu, T; Wei, F | 1 |
| Cloughesy, T; Green, RM; Lai, A; Nghiemphu, PL; Reardon, DA | 1 |
| Arcaroli, J; Cusatis, G; Garrett-Mayer, E; Hidalgo, M; Messersmith, WA; Rubio-Viqueira, B; Song, D; Weekes, CD; Wilson, LA; Winn, RA | 1 |
| Chen, X; Duvvuri, U; Fung, C; Grandis, JR | 1 |
| Jappe, A; Jehl, V; Johnson, BE; Klimovsky, J; Papadimitrakopoulou, VA; Soria, JC | 1 |
| Al-Shahrour, F; Alexander, D; Baran, M; Carretero, J; Difilippantonio, S; El Meskini, R; Guerin, T; Gumprecht, M; Iacovelli, AJ; Kozlov, S; Kulaga, A; Martin, PL; McCann, T; Mena, S; Schlomer, J; Van Dyke, T; Weaver, Z; Wong, KK | 1 |
| Deng, ZL; Dong, YC; Han, QL; Jiang, T; Lv, XH; Ren, H; Xing, WJ; Zou, Y | 1 |
| Gemma, A; Saito, Y | 1 |
| Arias-Pulido, H; Bauman, JE; Bishop, J; Chung, CH; Fekrazad, MH; Fertig, E; Howard, J; Jones, DV; Lee, SJ; Olson, GT; Ozawa, H; Spafford, MJ; Wang, H | 1 |
| Okamoto, T; Onda, S | 1 |
| Boeck, S; Haas, M; Heinemann, V; Holdenrieder, S; Kern, C; Nagel, D; Stieber, P; Wittwer, C | 1 |
| Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Atkey, N; Bolton, LM; Cree, IA; Dyson, M; Glaysher, S; Johnson, P; Torrance, C | 1 |
| Botting, GM; Fong, JT; Jacobs, RJ; Moravec, DN; Nlend, M; Puri, N; Uppada, SB | 1 |
| Bennouna, J; Besse, B; Blais, N; Gogov, S; Jehl, V; Johnson, BE; Leighl, N; Miller, N; Papadimitrakopoulou, VA; Soria, JC; Traynor, AM | 1 |
| Abrams, MB; Kjell, J; Olson, L; Pernold, K | 1 |
| Benhadji, KA; Brail, LH; Bumgardner, W; Cohen, EE; Hollebecque, A; Houédé, N; Italiano, A; Massard, C; Miller, J; Soria, JC; Westwood, P | 1 |
| Aldape, KD; Chang, SM; Cloughesy, TF; Dancey, J; Drappatz, J; Gilbert, MR; Groves, MD; Kuhn, JG; Lamborn, KR; Lieberman, FS; Ligon, AH; Ligon, KL; Mehta, MP; Norden, AD; Prados, MD; Robins, HI; Santagata, S; Wen, PY; Wright, JJ; Yung, WK | 1 |
| Bolton, LM; Cree, IA; Glaysher, S; Johnson, P; Torrance, C | 1 |
| Takahashi, M | 1 |
| Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W | 1 |
| Baladandayuthapani, V; Bekele, BN; Dai, B; Jayachandran, G; Ji, L; Kawashima, H; Lara-Guerra, H; Majidi, M; Mehran, R; Meng, F; Roth, JA; Sakai, R; Wang, J; Wang, Y; Yan, S; Ying, J; Yoo, SY | 1 |
| Huang, K; Liu, D | 1 |
| Mehra, R; Zibelman, M | 1 |
| Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
| Burris, HA; Clemett, D; Cohen, RB; Curt, G; Emeribe, U; Infante, JR; Kim, KB; LoRusso, PM; Tomkinson, HK | 1 |
| Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonneville-Levard, A; Chauffert, B; Chevreau, C; Cupissol, D; Duffaud, F; Fabbro, M; Feuvret, L; Le Cesne, A; Lebellec, L; Mir, O; Noel, G; Penel, N; Saada-Bouzid, E; Vauleon, E; Vinceneux, A | 1 |
| Aoki, M; Fujishita, T; Kajino-Sakamoto, R; Kojima, Y; Taketo, MM | 1 |
| Beccaria, K; Blauwblomme, T; Boddaert, N; Bolle, S; Brunelle, F; Calmon, R; Castel, D; Dhermain, F; Dufour, C; Grevent, D; Grill, J; Puget, S; Sainte-Rose, C; Saitovitch, A; Varlet, P; Zilbovicius, M | 1 |
| Amatruda, JF; Ateek, C; Budhipramono, A; Chen, KS; Frazier, AL; Fustino, NJ; Kapur, P; Laetsch, TW; Looijenga, LHJ; Lum, L; Rakheja, D; Shukla, AA; Stroup, EK; Stuart, SH; Yamaguchi, K | 1 |
| Go, H; Hong, BS; Lee, JL; Park, I; Shim, YS | 1 |
| Diab, Y; Diamond, C; Duchatelet, S; Hill, I; Hovnanian, A; Kirkorian, AY; Lakdawala, N; Marathe, K; Richard, G; Siegel, DH; Tower, RL; Watanabe, F; Zhang, A | 1 |
| Burke, CA; Chick, RC; Cindass, JL; Clifton, GT; Ensley, DC; Hale, DF; Hickerson, AT; Kemp Bohan, PM; Mankaney, G; Peoples, GE; Sohn, V; Vreeland, TJ | 1 |
| Brockman, AA; Esbenshade, AJ; Geben, LC; Ihrie, RA; Mobley, BC; Naftel, R; Pastakia, D | 1 |
| Govindan, R; Larson, S; Lockhart, AC; Luo, J; Morgensztern, D; Park, H; Suresh, R; Tan, B; Trikalinos, NA; Van Tine, BA; Wang-Gillam, A; Waqar, S; Williams, K | 1 |
13 review(s) available for erlotinib hydrochloride and sirolimus
| Article | Year |
|---|---|
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2007 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
[Targeted therapy for locally advanced and/or metastatic bladder cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Palliative chemotherapy for pancreatic malignancies.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Capecitabine; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Immunosuppressive Agents; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Palliative Care; Pancreatic Neoplasms; Quality of Life; Quinazolines; Sirolimus | 2010 |
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Cell Cycle; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wnt Proteins | 2010 |
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases | 2015 |
Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Azepines; Carcinoma, Squamous Cell; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinazolinones; Signal Transduction; Sirolimus | 2016 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Chemoprevention in familial adenomatous polyposis: past, present and future.
Topics: Adenomatous Polyposis Coli; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antineoplastic; Ascorbic Acid; Aspirin; Capsules; Celecoxib; Chemoprevention; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Eflornithine; Erlotinib Hydrochloride; Fatty Acids, Nonesterified; Genes, APC; Humans; Sirolimus; Sulindac; TOR Serine-Threonine Kinases; Vitamins | 2021 |
15 trial(s) available for erlotinib hydrochloride and sirolimus
| Article | Year |
|---|---|
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Central Nervous System Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome | 2010 |
Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Phosphorylation; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases | 2010 |
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Treatment Outcome | 2011 |
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Feasibility Studies; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Sirolimus; Survival Rate; Tissue Distribution | 2012 |
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Tissue Distribution | 2012 |
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Class I Phosphatidylinositol 3-Kinases; Cyclin-Dependent Kinase Inhibitor p16; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Platinum; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; Ribosomal Protein S6 Kinases; Sirolimus; Survival Rate; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2013 |
Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Albumins; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Biomarkers, Tumor; CA-19-9 Antigen; Capecitabine; Carcinoembryonic Antigen; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Keratin-19; Middle Aged; Multivariate Analysis; Oximes; Paclitaxel; Palliative Care; Pancreatic Neoplasms; Piperazines; Prospective Studies; Quinazolines; Sirolimus; Sulfonamides; Survival Rate | 2013 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
Phase II study of everolimus-erlotinib in previously treated patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Treatment Outcome | 2014 |
A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Everolimus; Fatigue; Female; Humans; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; Sirolimus; Time Factors; Treatment Outcome; Vomiting | 2014 |
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Survival Rate; Tissue Distribution; Young Adult | 2014 |
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Sirolimus | 2017 |
A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cohort Studies; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Phosphatidylinositol 3-Kinase; Sirolimus; Treatment Outcome | 2021 |
47 other study(ies) available for erlotinib hydrochloride and sirolimus
| Article | Year |
|---|---|
Combining targeted agents in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2004 |
Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells.
Topics: Cell Division; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Kinases; PTEN Phosphohydrolase; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Transfection | 2006 |
Signaling interactions of rapamycin combined with erlotinib in cervical carcinoma xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Epidermal Growth Factor; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Mice; Mice, SCID; Neoplasm Transplantation; Neoplasms, Experimental; Phosphorylation; Quinazolines; Ribosomal Protein S6; Signal Transduction; Sirolimus; Transplantation, Heterologous; Uterine Cervical Neoplasms | 2006 |
Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2006 |
Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays.
Topics: Adenocarcinoma; Animals; Biopsy, Fine-Needle; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Pancreatic Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Xenograft Model Antitumor Assays | 2007 |
Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression; Gene Expression Profiling; Growth Inhibitors; Head and Neck Neoplasms; Humans; Immunohistochemistry; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2007 |
Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.
Topics: Antibiotics, Antineoplastic; Benzamides; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Renal Cell; Cell Cycle; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Kidney Neoplasms; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2007 |
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Everolimus; Humans; Immunosuppressive Agents; Mice; Mice, Nude; Nerve Sheath Neoplasms; Protein Kinases; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Up-Regulation | 2008 |
Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Humans; Kidney Neoplasms; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2008 |
Rapamycin prevents transforming growth factor-alpha-induced pulmonary fibrosis.
Topics: Animals; Carrier Proteins; Collagen; Disease Models, Animal; Disease Progression; Doxycycline; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation; Humans; Lung; Mice; Mice, Transgenic; Phosphatidylinositol 3-Kinases; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pulmonary Fibrosis; Quinazolines; Respiratory Mechanics; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; Time Factors; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha; Uteroglobin | 2009 |
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells.
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biliary Tract Neoplasms; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Mitogen-Activated Protein Kinases; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2009 |
An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris.
Topics: Acantholysis; Animals; Apoptosis; Betacellulin; Carrier Proteins; Disease Models, Animal; Enzyme Activation; Epidermal Growth Factor; Epidermis; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunoglobulin G; Intercellular Signaling Peptides and Proteins; Intradermal Tests; Isoenzymes; Mice; Mice, Inbred C57BL; Pemphigus; Phosphotransferases (Alcohol Group Acceptor); Proto-Oncogene Proteins c-akt; Pyrazoles; Pyrimidines; Quinazolines; Sirolimus; src-Family Kinases; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha | 2009 |
The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Humans; Immunosuppressive Agents; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Purines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirolimus; Tumor Cells, Cultured | 2010 |
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Sirolimus; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenopus Proteins | 2010 |
Targeted therapy at the end of life for patients with lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Delivery Systems; Drug Utilization; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Singapore; Sirolimus; Terminal Care; Time Factors; Treatment Outcome | 2010 |
Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase II as Topic; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Immunosuppressive Agents; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Repressor Proteins; RNA Interference; Signal Transduction; Sirolimus; Survival Analysis; Survivin; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Small tumors, intermediate models, big hopes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunosuppressive Agents; Intracellular Signaling Peptides and Proteins; Mice; Mice, Transgenic; Neuroendocrine Tumors; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Sirolimus; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chromatography, Liquid; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Tandem Mass Spectrometry | 2010 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Combining an EGFR directed tyrosine kinase inhibitor with autophagy-inducing drugs: a beneficial strategy to combat non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Lung Neoplasms; Membrane Potential, Mitochondrial; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Sirolimus; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2011 |
Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Invasiveness; Quinazolines; Sarcoma; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2011 |
Erlotinib antagonizes constitutive activation of SRC family kinases and mTOR in acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Biomarkers, Tumor; Enzyme Activation; Erlotinib Hydrochloride; Flow Cytometry; G1 Phase Cell Cycle Checkpoints; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Microscopy, Electron; Microscopy, Fluorescence; Microtubule-Associated Proteins; Phosphorylation; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; src-Family Kinases; Stilbenes; TOR Serine-Threonine Kinases | 2011 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Child; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Young Adult | 2012 |
Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; MAP Kinase Signaling System; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sirolimus; TOR Serine-Threonine Kinases | 2012 |
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer.
Topics: Animals; Cell Line, Tumor; Chemokine CXCL12; Cyclin D1; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridines; Quinazolines; Receptors, CXCR; Receptors, CXCR4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Transplantation, Heterologous; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2012 |
EGFR tyrosine kinase inhibition induces autophagy in cancer cells.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 7; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; HeLa Cells; Humans; Lung Neoplasms; Mouth Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Sirolimus; Ubiquitin-Activating Enzymes | 2012 |
Temporal molecular and biological assessment of an erlotinib-resistant lung adenocarcinoma model reveals markers of tumor progression and treatment response.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Transcription Factors | 2012 |
Effects of epidermal growth factor receptor and phosphatase and tensin homologue gene expression on the inhibition of U87MG glioblastoma cell proliferation induced by protein kinase inhibitors.
Topics: Butadienes; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Furans; Gene Expression; Glioblastoma; Humans; Nitriles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
[Lung injury].
Topics: Antineoplastic Agents; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Lung Diseases; Quinazolines; Sirolimus | 2012 |
[Pancreatic carcinoma].
Topics: Erlotinib Hydrochloride; Everolimus; Humans; Molecular Targeted Therapy; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2012 |
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies.
Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Targeting EGFR and PI3K pathways in ovarian cancer.
Topics: Antibiotics, Antineoplastic; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Triazines; Tumor Cells, Cultured | 2013 |
Alternative signaling pathways as potential therapeutic targets for overcoming EGFR and c-Met inhibitor resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Indoles; Lung Neoplasms; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Sirolimus; Sulfonamides; TOR Serine-Threonine Kinases; Wnt Proteins | 2013 |
Oral erlotinib, but not rapamycin, causes modest acceleration of bladder and hindlimb recovery from spinal cord injury in rats.
Topics: Administration, Oral; Animals; Disease Models, Animal; Erlotinib Hydrochloride; Female; Hindlimb; Immunosuppressive Agents; Locomotion; Protein Kinase Inhibitors; Quinazolines; Rats, Sprague-Dawley; Recovery of Function; Sirolimus; Spinal Cord Injuries; Urinary Bladder | 2014 |
Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.
Topics: Breast; Cell Line; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazines | 2014 |
[Erlotinib, sunitinib, and everolimus].
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Erlotinib Hydrochloride; Everolimus; Humans; Indoles; Pancreatic Neoplasms; Pyrroles; Quinazolines; Sirolimus; Sunitinib | 2015 |
Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
Topics: Animals; Apoptosis; Benzamides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Neoplasm Metastasis; Piperazines; Pyrazoles; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Treatment Outcome; Tumor Stem Cell Assay; Tumor Suppressor Proteins | 2015 |
Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Hydroxychloroquine; RNA, Small Interfering; Sirolimus; Tongue Neoplasms; Up-Regulation | 2016 |
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydrochloride; Female; France; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Skull Base Neoplasms; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gene Expression Regulation, Neoplastic; HCT116 Cells; HT29 Cells; Humans; Intestinal Neoplasms; MAP Kinase Signaling System; Mice, 129 Strain; Mice, Inbred C57BL; Morpholines; Neoplasm Invasiveness; Sirolimus; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2017 |
Multimodal Magnetic Resonance Imaging of Treatment-Induced Changes to Diffuse Infiltrating Pontine Gliomas in Children and Correlation to Patient Progression-Free Survival.
Topics: Adolescent; Antineoplastic Agents; Brain; Brain Stem Neoplasms; Chemotherapy, Adjuvant; Child; Child, Preschool; Contrast Media; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Glioma; Humans; Magnetic Resonance Imaging; Male; Prospective Studies; Sirolimus; Statistics, Nonparametric; Survival Analysis; Time Factors; Tumor Burden | 2017 |
EGF Receptor and mTORC1 Are Novel Therapeutic Targets in Nonseminomatous Germ Cell Tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Interleukin Receptor Common gamma Subunit; Mechanistic Target of Rapamycin Complex 1; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Neoplasms, Germ Cell and Embryonal; Sirolimus; Testicular Neoplasms; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Leiomyomatosis; Male; Neoplasms, Multiple Primary; Neoplastic Syndromes, Hereditary; Sirolimus; Skin Neoplasms; Time Factors; Treatment Failure; Uterine Neoplasms | 2019 |
Targeted Inhibition of the Epidermal Growth Factor Receptor and Mammalian Target of Rapamycin Signaling Pathways in Olmsted Syndrome.
Topics: Adolescent; Brazil; Child; Child, Preschool; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunosuppressive Agents; Infant; Keratoderma, Palmoplantar; Male; Protein Kinase Inhibitors; Signal Transduction; Sirolimus; Syndrome; TOR Serine-Threonine Kinases; Treatment Outcome | 2020 |
Sustained response to erlotinib and rapamycin in a patient with pediatric anaplastic oligodendroglioma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Erlotinib Hydrochloride; Female; Humans; Oligodendroglioma; Prognosis; Remission Induction; Sirolimus | 2021 |